VTRS vs. WST: Viatris vs. West Pharmaceutical Services Stock Comparison

November 11, 2026

How do Viatris (VTRS) and West Pharmaceutical Services (WST) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Viatris (VTRS) and West Pharmaceutical Services (WST) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but VTRS is classified in Pharmaceuticals while WST is classified in Life Sciences Tools & Services.

Company profile comparison for Viatris (VTRS) and West Pharmaceutical Services (WST)
Profile Item	VTRS	WST
Name	Viatris Inc.	West Pharmaceutical Services Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Pharmaceuticals	Life Sciences Tools & Services
GICS Sub-Industry	Pharmaceuticals	Life Sciences Tools & Services
Market Capitalization	22.83 billion USD	27.85 billion USD
Currency	USD	USD
Exchange	Nasdaq	NYSE
Listing Date	March 17, 1980	March 17, 1980
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

VTRS

WST

GSPC

Viatris (VTRS) vs. West Pharmaceutical Services (WST), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Viatris (VTRS) and West Pharmaceutical Services (WST). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Viatris (VTRS) and West Pharmaceutical Services (WST). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Viatris (VTRS) and West Pharmaceutical Services (WST)
Metric	VTRS	WST
Total Return (1Y)	108.98%	51.68%
Total Return (3Y, Annualized)	36.75%	7.13%
Total Return (5Y, Annualized)	11.59%	0.05%

Risk Profile

Drawdown History

VTRS

WST

GSPC

Viatris (VTRS) vs. West Pharmaceutical Services (WST), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Viatris (VTRS) and West Pharmaceutical Services (WST). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Viatris (VTRS) and West Pharmaceutical Services (WST)
Metric	VTRS	WST
Volatility (1Y, Annualized)	32.53%	31.45%
Beta (5Y)	0.86	1.13
Max Drawdown (5Y)	-45.69%	-59.29%
Avg. Volume (3M)	8.87M	603.86K

Risk-Adjusted Performance

Risk-Return Positioning

VTRS and WST are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Viatris (VTRS) and West Pharmaceutical Services (WST)
Metric	VTRS	WST
Sharpe Ratio (1Y)	3.22	1.51
Sortino Ratio (1Y)	5.63	2.35

Profitability

ROE (TTM)

Viatris (VTRS) reports a negative ROE of -4.21%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile West Pharmaceutical Services (WST) reports 21.23%, ranking against industry peers normally.

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

-4.21%

Max: 109.18%
Q3: 6.23%
VTRS: -4.21%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

WST

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.23%

Max: 109.18%
WST: 21.23%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Viatris (VTRS) vs. West Pharmaceutical Services (WST): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Viatris (VTRS) reports a negative net margin of -4.13%, usually indicating a net loss over the period. Meanwhile West Pharmaceutical Services (WST) reports 18.81%, ranking against industry peers normally.

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

-4.13%

Max: 18.05%
Q3: 4.78%
Median: 0.00%
VTRS: -4.13%
Q1: -4.14%
Min: -17.05%

WST

Pharmaceuticals, Biotechnology & Life Sciences industry group

18.81%

WST: 18.81%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Viatris (VTRS) vs. West Pharmaceutical Services (WST): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

West Pharmaceutical Services (WST) at 25.37% operates in the top operating margin quartile, ahead of Viatris (VTRS) at 13.85%, which runs around its industry’s norm.

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.85%

Max: 83.12%
Q3: 14.77%
VTRS: 13.85%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

WST

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.37%

Max: 83.12%
WST: 25.37%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Viatris (VTRS) vs. West Pharmaceutical Services (WST): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Viatris (VTRS) and West Pharmaceutical Services (WST)
Metric	VTRS	WST
ROE (TTM)	-4.21%	21.23%
ROA (TTM)	2.91%	11.89%
Net Margin (TTM)	-4.13%	18.81%
Operating Margin (TTM)	13.85%	25.37%
Gross Margin (TTM)	41.13%	37.59%

Growth

Revenue Growth

West Pharmaceutical Services (WST) at 6.25% is around its peer norm for revenue growth, while Viatris (VTRS) at -2.98% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Viatris (VTRS) vs. West Pharmaceutical Services (WST): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: West Pharmaceutical Services (WST) reports EPS growth of 1.49%, ranked against its industry; Viatris (VTRS) has no EPS growth figure this period.

Viatris (VTRS) vs. West Pharmaceutical Services (WST): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Viatris (VTRS) and West Pharmaceutical Services (WST)
Metric	VTRS	WST
Revenue Growth (YoY)	-2.98%	6.25%
Revenue Growth (3Y CAGR)	-4.20%	2.12%
EPS Growth (YoY)	--	1.49%
EPS Growth (3Y CAGR)	--	-4.23%

Financial Strength

Current Ratio (MRQ)

West Pharmaceutical Services (WST) at 2.82 keeps current ratio within its industry’s typical mid-range, while Viatris (VTRS) at 1.55 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for VTRS.

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.55

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
VTRS: 1.55
Min: 0.10

WST

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.82

Max: 25.13
Q3: 12.13
Median: 5.52
WST: 2.82
Q1: 2.47
Min: 0.10

Viatris (VTRS) vs. West Pharmaceutical Services (WST): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

West Pharmaceutical Services (WST) at 0.11 carries an industry-typical debt-to-equity mix, while Viatris (VTRS) at 0.99 uses more debt funding than most peers.

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.99

Max: 1.42
VTRS: 0.99
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

WST

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.11

Max: 1.42
Q3: 0.65
Median: 0.15
WST: 0.11
Q1: 0.02
Min: 0.00

Viatris (VTRS) vs. West Pharmaceutical Services (WST): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Viatris (VTRS) and West Pharmaceutical Services (WST)
Metric	VTRS	WST
Current Ratio (MRQ)	1.55	2.82
Debt / Equity (MRQ)	0.99	0.11
Net Debt / EBITDA	2.64	-0.16

Dividends

Dividend Yield (TTM)

Both Viatris (VTRS) at 2.53% and West Pharmaceutical Services (WST) at 0.22% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.53%

VTRS: 2.53%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

WST

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.22%

WST: 0.22%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Viatris (VTRS) vs. West Pharmaceutical Services (WST): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Viatris (VTRS) reports payout ratio above 100% at 960.00%, meaning dividends exceeded current-period earnings and sustainability needs extra context. Meanwhile West Pharmaceutical Services (WST) reports 9.88%, ranking against industry peers normally.

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

960.00%

VTRS: 960.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

WST

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.88%

WST: 9.88%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Viatris (VTRS) vs. West Pharmaceutical Services (WST): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Viatris (VTRS) and West Pharmaceutical Services (WST)
Metric	VTRS	WST
Dividend Yield (TTM)	2.53%	0.22%
Dividend Payout Ratio (TTM)	960.00%	9.88%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: West Pharmaceutical Services (WST) trades at 44.87 times trailing earnings, ranked against its peers, while Viatris (VTRS) has no P/E ratio this period.

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
VTRS: --

WST

Pharmaceuticals, Biotechnology & Life Sciences industry group

44.87

Max: 85.34
WST: 44.87
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

Viatris (VTRS) vs. West Pharmaceutical Services (WST): VTRS does not report P/E ratio, so it has no value marker; WST is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

Viatris (VTRS) at 1.55 sits in the cheaper P/S ratio quartile while West Pharmaceutical Services (WST) at 8.20 prices around its industry’s middle — VTRS costs less per dollar of sales, though read it alongside growth and margins.

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.55

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
VTRS: 1.55
Min: 0.01

WST

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.20

Max: 58.18
Q3: 25.77
WST: 8.20
Median: 7.30
Q1: 3.01
Min: 0.01

Viatris (VTRS) vs. West Pharmaceutical Services (WST): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Viatris (VTRS) at 1.67 looks cheap against book in the lower P/B ratio quartile, while West Pharmaceutical Services (WST) at 9.40 carries a premium in the upper quartile — a clear price-to-book gap.

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.67

Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
VTRS: 1.67
Min: -5.59

WST

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.40

Max: 13.53
WST: 9.40
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

Viatris (VTRS) vs. West Pharmaceutical Services (WST): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Viatris (VTRS) and West Pharmaceutical Services (WST)
Metric	VTRS	WST
P/E Ratio (TTM)	--	44.87
P/S Ratio (TTM)	1.55	8.20
P/B Ratio (MRQ)	1.67	9.40
Free Cash Flow Yield (TTM)	13.84%	1.24%